Ieq Capital LLC Invests $835,000 in Intellia Therapeutics, Inc. $NTLA

Ieq Capital LLC acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the second quarter, HoldingsChannel.com reports. The firm acquired 49,375 shares of the company’s stock, valued at approximately $835,000.

Several other institutional investors have also recently added to or reduced their stakes in NTLA. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics in the 3rd quarter worth about $30,000. Advisory Services Network LLC purchased a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $33,000. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the second quarter worth approximately $26,000. Comerica Bank boosted its position in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the last quarter. Finally, Danske Bank A S purchased a new stake in Intellia Therapeutics in the third quarter valued at approximately $50,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NTLA has been the subject of several research analyst reports. Citizens Jmp reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective for the company in a report on Friday, August 7th. Sanford C. Bernstein increased their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.15.

Insider Activity

In other news, EVP Edward J. Dulac III sold 4,677 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at $2,813,148. This represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.50% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $13.11 on Friday. Intellia Therapeutics, Inc. has a one year low of $7.95 and a one year high of $28.25. The company’s 50 day moving average price is $13.31 and its 200 day moving average price is $13.38. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -3.90 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. During the same quarter last year, the firm posted ($0.98) EPS. The business’s revenue for the quarter was down 46.4% compared to the same quarter last year. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.